Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL

PURPOSE: CD19-targeted chimeric antigen receptor T cells (CD19-CAR) and blinatumomab effectively induce remission in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) but are also associated with CD19 antigen modulation. There are limited data regarding the impact of prior blinatumoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Myers, Regina M., Taraseviciute, Agne, Steinberg, Seth M., Lamble, Adam J., Sheppard, Jennifer, Yates, Bonnie, Kovach, Alexandra E., Wood, Brent, Borowitz, Michael J., Stetler-Stevenson, Maryalice, Yuan, Constance M., Pillai, Vinodh, Foley, Toni, Chung, Perry, Chen, Lee, Lee, Daniel W., Annesley, Colleen, DiNofia, Amanda, Grupp, Stephan A., John, Samuel, Bhojwani, Deepa, Brown, Patrick A., Laetsch, Theodore W., Gore, Lia, Gardner, Rebecca A., Rheingold, Susan R., Pulsipher, Michael A., Shah, Nirali N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8937010/
https://www.ncbi.nlm.nih.gov/pubmed/34767461
http://dx.doi.org/10.1200/JCO.21.01405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8937010/
https://www.ncbi.nlm.nih.gov/pubmed/34767461
http://dx.doi.org/10.1200/JCO.21.01405

Ejemplares similares